FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely pharmacology, and concerns the use of 2-[(1,1'-biphenyl)-4-yl]imidazo[2,1-a]isoquinoline of formula I: 
, as a compound exhibiting both AMPA-activating and PTP1B-inhibitory action.
EFFECT: proposed antidiabetic means.
1 cl, 2 dwg, 2 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HYDROBROMID 4'-(2,3-DIGIDRO-9H-IMIDAZO[1,2-A]BENZIMIDAZOLE-9-YL-METHYL)BIPHENYL-2-CARBONITRIL EXHIBITING THE PROPERTIES OF THE ACTIVATOR OF AMP-ACTIVATED PROTEINKINASE (AMPA) | 2017 |
|
RU2650877C1 |
| BROMIDES OF BENZIMIDAZOLIUM DERIVATIVES AS INHIBITORS OF PROTEIN-TYROSINEPHOSPHATASE 1B TYPE (PTP1B) | 2018 |
|
RU2652112C1 |
| GEROPROTECTOR FOR MODEL ANIMALS | 2016 |
|
RU2639500C1 |
| APPLICATION OF THIENOPYRIDONE DERIVATIVES AS AMPA-ACTIVATORS AND PHARMACEUTIC COMPOSITIONS, CONTAINING THEM | 2006 |
|
RU2416409C2 |
| METHOD FOR PREDICTION OF PROGRESSIVE CLINICAL COURSE OF EARLY FORMS OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2020 |
|
RU2768466C1 |
| USE OF TETRAACETYLATED 5-AMINO-4-CARBAMOYL IMIDAZOLYL-1-β-D-RIBOFURANOSIDE AS A PROTEIN KINASE Cδ INHIBITOR | 2019 |
|
RU2712150C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2020 |
|
RU2753793C1 |
| METHOD OF PREDICTING RISK OF DEVELOPING DIABETIC FOOT SYNDROME IN RESIDENTS OF CENTRAL RUSSIA WITH TYPE 2 DIABETES MELLITUS BASED ON GENOTYPING OF RS7517862 POLYMORPHISM OF ATF6 GENE | 2023 |
|
RU2811753C1 |
| METHOD OF ISOLATION OF NEW GLYCOSIDES FROM PTEROCARPUS MARSUPIUM AND THEIR THERAPEUTIC EFFECTS | 2019 |
|
RU2799555C1 |
| PEPTIDE THAT SPECIFICALLY INTERACTS WITH THE HUMAN IMMUNE RESPONSE CONTROL MOLECULE B7-2 (CD86) | 2022 |
|
RU2808419C1 |
